目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY
2.1 RESEARCH APPROACH
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key objectives of secondary research
2.1.2 PRIMARY DATA
2.1.2.1 Breakdown of primaries
2.1.2.2 Key objectives of primary research
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
2.2.2 MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH
2.2.3 DEMAND AND SUPPLY-SIDE ANALYSIS
2.2.4 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN CRO SERVICES MARKET
3.3 DISRUPTIVE TRENDS SHAPING CRO SERVICES MARKET
3.4 HIGH GROWTH SEGMENTS AND EMERGING FRONTIERS

4 PREMIUM INSIGHTS
4.1 GLOBAL CRO SERVICES MARKET SNAPSHOT
4.2 NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY AND COUNTRY, 2024
4.3 CRO SERVICES MARKET, BY TYPE, 2024
4.4 CRO SERVICES MARKET, BY END USER, 2024
4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.6 UNMET NEEDS AND WHITE SPACES
4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
4.8 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFT
4.9 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.10 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising clinical trial volume and escalating protocol complexity
5.2.1.2 Growing focus on decentralized/patient-centric trials
5.2.1.3 Increasing preference for service flexibility
5.2.1.4 Technological integration
5.2.1.5 Growing R&D budgets and expanding late-stage pipelines
5.2.2 OPPORTUNITIES
5.2.2.1 Shift toward regulatory compliance
5.2.2.2 Growing adoption of risk-based monitoring
5.2.2.3 Favorable reimbursement scenario
5.2.3 CHALLENGES
5.2.3.1 Patient retention
5.2.3.2 Cybersecurity and intellectual property challenges

6 INDUSTRY TRENDS
6.1 MARKET TRENDS
6.1.1 HEALTH ECONOMICS & OUTCOMES RESEARCH AND REAL-WORLD EVIDENCE
6.1.2 IN-SILICO TRIALS
6.1.3 SPECIALIZED ANALYTICS FOR EMERGING MODALITIES
6.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
6.3 PRICING ANALYSIS
6.3.1 INDICATIVE PRICING ANALYSIS, BY SERVICE TYPE
6.3.2 INDICATIVE PRICING ANALYSIS, BY PHASE
6.3.3 INDICATIVE PRICING ANALYSIS, BY REGION
6.4 VALUE CHAIN ANALYSIS
6.5 ECOSYSTEM ANALYSIS
6.6 INVESTMENT/FUNDING ACTIVITY
6.7 TECHNOLOGY ANALYSIS
6.7.1 KEY TECHNOLOGIES
6.7.1.1 Clinical trial management system
6.7.1.2 Randomization and trial supply management
6.7.1.3 Electronic Data Capture (EDC) system
6.7.2 COMPLEMENTARY TECHNOLOGIES
6.7.2.1 Model-informed drug development
6.7.2.2 Data management and informatics technologies
6.7.3 ADJACENT TECHNOLOGIES
6.7.3.1 Clinical trial simulation tools
6.8 KEY CONFERENCES AND EVENTS
6.9 REGULATORY LANDSCAPE
6.9.1 REGULATORY FRAMEWORK
6.9.1.1 North America
6.9.1.2 Europe
6.9.1.3 Asia Pacific
6.9.1.4 Rest of the World
6.9.2 REGULATORY ANALYSIS
6.9.3 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.9.4 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES
6.10 PORTER'S FIVE FORCES ANALYSIS
6.10.1 BARGAINING POWER OF SUPPLIERS
6.10.2 BARGAINING POWER OF BUYERS
6.10.3 THREAT OF NEW ENTRANTS
6.10.4 THREAT OF SUBSTITUTES
6.10.5 INTENSITY OF COMPETITIVE RIVALRY
6.11 KEY STAKEHOLDERS AND BUYING CRITERIA
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
6.11.2 BUYING CRITERIA
6.12 CUSTOMER LANDSCAPE
6.12.1 BUDGET ALLOCATION TREND
6.12.2 ADOPTION BARRIER AND INTERNAL FRICTION
6.13 IMPACT OF AI/GEN AI ON CRO SERVICES MARKET
6.13.1 INTRODUCTION
6.13.2 MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES
6.13.3 AI USE CASES
6.13.4 KEY COMPANIES IMPLEMENTING AI
6.13.5 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM
6.14 IMPACT OF 2025 TRUMP TARIFF ON CRO SERVICES MARKET
6.14.1 INTRODUCTION
6.14.2 KEY TARIFF RATES
6.14.3 PRICE IMPACT ANALYSIS
6.14.4 IMPACT ON COUNTRY/REGION
6.14.4.1 North America (US)
6.14.4.2 Europe
6.14.4.3 Asia Pacific
6.14.5 IMPACT ON END-USE INDUSTRIES
6.14.5.1 Pharmaceutical & biotech companies
6.14.5.2 Medical device companies
6.14.5.3 Academic institutes

7 CRO SERVICES MARKET, BY TYPE
7.1 INTRODUCTION
7.2 CLINICAL RESEARCH SERVICES
7.2.1 PHASE III
7.2.1.1 Large-scale testing ability to assess efficacy and safety of drugs to aid growth
7.2.2 PHASE II
7.2.2.1 Growing number of pipeline products in Phase II studies to drive market
7.2.3 PHASE I
7.2.3.1 Robust pipeline of pharmaceutical and biopharmaceutical products to support growth
7.2.4 PHASE IV
7.2.4.1 Stringent global regulations for drug safety monitoring to spur growth
7.3 EARLY PHASE DEVELOPMENT SERVICES
7.3.1 CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES
7.3.1.1 Growing need to meet regulatory norms for drugs to fuel market
7.3.2 PRECLINICAL SERVICES
7.3.2.1 Pharmacokinetics/Pharmacodynamics
7.3.2.1.1 Rise in outsourcing services by pharmaceutical and biopharmaceutical companies to promote growth
7.3.2.2 Toxicology testing
7.3.2.2.1 Need to prevent late-stage failures to contribute to growth
7.3.2.3 Other preclinical services
7.3.3 DISCOVERY STUDIES
7.3.3.1 Increasing reliance on CRO services for target identification and validation to expedite growth
7.4 LABORATORY SERVICES
7.4.1 ANALYTICAL TESTING
7.4.1.1 Physical characterization
7.4.1.1.1 Ability to minimize product failure in late-phase development to favor growth
7.4.1.2 Raw material testing
7.4.1.2.1 Need to maintain quality of finished product to facilitate growth
7.4.1.3 Batch-release testing
7.4.1.3.1 Need to maintain batch-to-batch consistency of pharmaceutical dosage forms to advance growth
7.4.1.4 Stability testing
7.4.1.4.1 Ability to establish drug compatibility and formulation development to aid growth
7.4.1.5 Other analytical testing services
7.4.2 BIOANALYTICAL TESTING
7.4.2.1 Increasing outsourcing of R&D activities to accelerate growth
7.5 CONSULTING SERVICES
7.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO BOOST MARKET
7.6 DATA MANAGEMENT SERVICES
7.6.1 NEED TO TRACK PROGRESS OF EARLY DRUG DEVELOPMENT TO AUGMENT GROWTH

8 CRO SERVICES MARKET, BY THERAPEUTIC AREA
8.1 INTRODUCTION
8.2 ONCOLOGY
8.2.1 BREAST CANCER
8.2.1.1 Increasing cases and high spending on treating breast cancer to support growth
8.2.2 LUNG CANCER
8.2.2.1 Increasing focus on developing drugs against lung cancer to foster growth
8.2.3 COLORECTAL CANCER
8.2.3.1 Increasing drug discovery and development efforts against colorectal cancer to aid growth
8.2.4 PROSTATE CANCER
8.2.4.1 Growing clinical pipeline to propel market
8.2.5 OTHER CANCERS
8.3 INFECTIOUS DISEASES
8.3.1 INCREASING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT GROWTH
8.4 CARDIOVASCULAR SYSTEM DISORDERS
8.4.1 HIGH MORTALITY RATES DUE TO CARDIOVASCULAR DISEASES TO FUEL MARKET
8.5 NEUROLOGY
8.5.1 GROWING INVESTMENTS IN NEUROLOGICAL DISORDER RESEARCH TO DRIVE MARKET
8.6 VACCINES
8.6.1 INCREASING FOCUS ON VACCINE DEVELOPMENT TO SPUR GROWTH
8.7 METABOLIC DISORDERS/ENDOCRINOLOGY
8.7.1 INCREASING GLOBAL DIABETES AND OBESITY POPULATION TO PROMOTE GROWTH
8.8 IMMUNOLOGICAL DISORDERS
8.8.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
8.9 PSYCHIATRY
8.9.1 RISING CASES OF PSYCHIATRIC DISORDERS AND DEPRESSION TO SUSTAIN GROWTH
8.10 RESPIRATORY DISORDERS
8.10.1 RISING INCIDENCE OF CHRONIC RESPIRATORY DISEASE TO FOSTER GROWTH
8.11 DERMATOLOGY
8.11.1 GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO DRIVE MARKET
8.12 OPHTHALMOLOGY
8.12.1 GROWTH IN OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT MARKET
8.13 GASTROINTESTINAL DISEASES
8.13.1 RAPID LIFESTYLE AND DIETARY CHANGES TO AMPLIFY GROWTH
8.14 GENITOURINARY & WOMEN'S HEALTH
8.14.1 RISING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS AND TREATMENT TO BOLSTER GROWTH
8.15 HEMATOLOGY
8.15.1 INCREASING DRUG APPROVALS FOR DRUGS AGAINST NON-MALIGNANT HEMATOLOGICAL CONDITIONS TO SUPPORT GROWTH
8.16 OTHER THERAPEUTIC AREAS

9 CRO SERVICES MARKET, BY MODALITY
9.1 INTRODUCTION
9.2 SMALL MOLECULES
9.2.1 ONGOING SURGE IN PHARMACEUTICAL R&D INVESTMENTS TO SUPPORT GROWTH
9.3 BIOLOGICS
9.3.1 MONOCLONAL ANTIBODY
9.3.1.1 Surging demand for targeted therapies across oncology, autoimmune disorders, and infectious diseases to drive market
9.3.2 CELL & GENE THERAPY
9.3.2.1 Robust drug pipeline and R&D initiatives to drive market
9.3.3 OTHER BIOLOGICS
9.4 MEDICAL DEVICES
9.4.1 RAPID INNOVATIONS IN DIAGNOSTICS, IMPLANTABLE, AND DIGITAL HEALTH TECHNOLOGIES TO FOSTER GROWTH
9.5 BIOSIMILARS
9.5.1 MONOCLONAL ANTIBODY BIOSIMILARS
9.5.1.1 Rising demand for affordable therapeutic options to support growth
9.5.2 INSULIN
9.5.2.1 Increasing patent expirations to contribute to growth
9.5.3 COLONY STIMULATING FACTOR
9.5.3.1 Increasing use of colony stimulating factor during post-chemotherapy to aid growth
9.5.4 ERYTHROPOEITIN
9.5.4.1 Essential role of erythropoietin in treating anemia to stimulate growth
9.5.5 OTHER BIOSIMILARS

10 CRO SERVICES MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
10.2.1 INCREASING OUTSOURCING AND PARTNERSHIPS TO ACCELERATE GROWTH
10.3 MEDICAL DEVICE COMPANIES
10.3.1 INCREASING RECOGNITION OF CRO PROVIDERS TO AUGMENT GROWTH
10.4 ACADEMIC INSTITUTES
10.4.1 CONSISTENT COLLABORATIONS BETWEEN CROS AND ACADEMIA TO INTENSIFY GROWTH

11 CRO SERVICES MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.2.1 Increasing incidence of oncology indications to accelerate growth
11.2.3 CANADA
11.2.3.1 Favorable government initiatives and high investments to support growth
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.2.1 Presence of strong pharmaceutical and biotechnology R&D infrastructure to spur growth
11.3.3 UK
11.3.3.1 Rising R&D expenditure in pharmaceutical industry to expedite growth
11.3.4 FRANCE
11.3.4.1 Increasing technological advancements and faster drug discovery and development initiatives to aid growth
11.3.5 ITALY
11.3.5.1 Short timeline for drug approvals to encourage growth
11.3.6 SPAIN
11.3.6.1 Growing investment in pharmaceutical industry to boost market
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 CHINA
11.4.2.1 Continued efforts on improving level of drug safety and supply to spur growth
11.4.3 INDIA
11.4.3.1 Large pool of patients and presence of highly skilled medical professionals to augment growth
11.4.4 JAPAN
11.4.4.1 Growing drug development activity to propel market
11.4.5 AUSTRALIA
11.4.5.1 Growing focus on funding opportunities to boost market
11.4.6 SOUTH KOREA
11.4.6.1 Emerging clinical research hub to sustain growth
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.2.1 Growing focus on enhancing pharmaceutical research and production to fuel market
11.5.3 MEXICO
11.5.3.1 Increasing investments in pharma R&D to promote growth
11.5.4 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC COUNTRIES
11.6.2.1 Kingdom of Saudi Arabia (KSA)
11.6.2.1.1 Expanding clinical trials ecosystem to contribute to growth
11.6.2.2 United Arab Emirates (UAE)
11.6.2.2.1 Growing clinical trials activity to drive market
11.6.2.2.2 Rest of GCC Countries
11.6.2.3 Rest of Middle East
11.7 AFRICA
11.7.1 BOOMING PHARMACEUTICAL INDUSTRY TO FACILITATE GROWTH
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET
12.3 REVENUE ANALYSIS, 2020-2024
12.4 MARKET SHARE ANALYSIS, 2024
12.5 COMPANY VALUATION AND FINANCIAL METRICS
12.6 BRAND/SERVICE COMPARISON
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
12.7.1 STARS
12.7.2 EMERGING LEADERS
12.7.3 PERVASIVE PLAYERS
12.7.4 PARTICIPANTS
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
12.7.5.1 Company footprint
12.7.5.2 Region footprint
12.7.5.3 Type footprint
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
12.8.1 PROGRESSIVE COMPANIES
12.8.2 RESPONSIVE COMPANIES
12.8.3 DYNAMIC COMPANIES
12.8.4 STARTING BLOCKS
12.8.5 COMPETITIVE BENCHMARKING
12.8.5.1 Detailed list of key startups/SMEs
12.8.5.2 Competitive benchmarking of key startups/SMEs
12.9 COMPETITIVE SCENARIO
12.9.1 SERVICE/SOLUTION LAUNCHES AND APPROVALS
12.9.2 DEALS
12.9.3 EXPANSIONS

13 COMPANY PROFILES
13.1 KEY PLAYERS
13.1.1 IQVIA INC.
13.1.1.1 Business overview
13.1.1.2 Services/Solutions offered
13.1.1.3 Recent developments
13.1.1.3.1 Service/Solution launches and approvals
13.1.1.3.2 Deals
13.1.1.3.3 Other developments
13.1.1.4 MnM view
13.1.1.4.1 Key strengths
13.1.1.4.2 Strategic choices
13.1.1.4.3 Weaknesses and competitive threats
13.1.2 ICON PLC
13.1.2.1 Business overview
13.1.2.2 Services/Solutions offered
13.1.2.3 Recent developments
13.1.2.3.1 Service/Solution launches and approvals
13.1.2.3.2 Deals
13.1.2.3.3 Expansions
13.1.2.4 MnM view
13.1.2.4.1 Key strengths
13.1.2.4.2 Strategic choices
13.1.2.4.3 Weaknesses and competitive threats
13.1.3 THERMO FISHER SCIENTIFIC INC.
13.1.3.1 Business overview
13.1.3.2 Services/Solutions offered
13.1.3.3 Recent developments
13.1.3.3.1 Service/Solution launches and approvals
13.1.3.3.2 Deals
13.1.3.3.3 Expansions
13.1.3.4 MnM view
13.1.3.4.1 Key strengths
13.1.3.4.2 Strategic choices
13.1.3.4.3 Weaknesses and competitive threats
13.1.4 LABCORP
13.1.4.1 Business overview
13.1.4.2 Services/Solutions offered
13.1.4.3 Recent developments
13.1.4.3.1 Service/Solution launches and approvals
13.1.4.3.2 Deals
13.1.4.3.3 Expansions
13.1.4.3.4 Other developments
13.1.4.4 MnM view
13.1.4.4.1 Key strengths
13.1.4.4.2 Strategic choices
13.1.4.4.3 Weaknesses and competitive threats
13.1.5 FORTREA, INC.
13.1.5.1 Company overview
13.1.5.2 Services/Solutions offered
13.1.5.3 Recent developments
13.1.5.3.1 Service/Solution launches and approvals
13.1.5.3.2 Deals
13.1.5.3.3 Expansions
13.1.5.3.4 Other developments
13.1.5.4 MnM view
13.1.5.4.1 Key strengths
13.1.5.4.2 Strategic choices
13.1.5.4.3 Weaknesses and competitive threats
13.1.6 SYNEOS HEALTH
13.1.6.1 Business overview
13.1.6.2 Services/Solutions offered
13.1.6.3 Recent developments
13.1.6.3.1 Service/Solution launches and approvals
13.1.6.3.2 Deals
13.1.7 WUXI APPTEC
13.1.7.1 Business overview
13.1.7.2 Services/Solutions offered
13.1.7.3 Recent developments
13.1.7.3.1 Service/Solution launches and approvals
13.1.7.3.2 Deals
13.1.7.3.3 Expansions
13.1.8 CHARLES RIVER LABORATORIES
13.1.8.1 Business overview
13.1.8.2 Services/Solutions offered
13.1.8.3 Recent developments
13.1.8.3.1 Deals
13.1.8.3.2 Expansions
13.1.9 PAREXEL INTERNATIONAL CORPORATION
13.1.9.1 Business overview
13.1.9.2 Services/Solutions offered
13.1.9.3 Recent developments
13.1.9.3.1 Service/Solution launches and approvals
13.1.9.3.2 Deals
13.1.9.3.3 Expansions
13.1.10 PHARMARON
13.1.10.1 Business overview
13.1.10.2 Services/Solutions offered
13.1.11 MEDPACE
13.1.11.1 Business overview
13.1.11.2 Services/Solutions offered
13.1.12 SGS SOCIETE GENERALE DE SURVEILLANCE SA
13.1.12.1 Business overview
13.1.12.2 Services/Solutions offered
13.1.12.3 Recent developments
13.1.12.3.1 Deals
13.1.13 FRONTAGE LABS
13.1.13.1 Business overview
13.1.13.2 Services/Solutions offered
13.1.13.3 Recent developments
13.1.13.3.1 Deals
13.1.13.3.2 Expansions
13.1.13.3.3 Other developments
13.1.14 EUROFINS SCIENTIFIC
13.1.14.1 Business overview
13.1.14.2 Services/Solutions offered
13.1.14.3 Recent developments
13.1.14.3.1 Deals
13.1.15 TIGERMED
13.1.15.1 Business overview
13.1.15.2 Services/Solutions offered
13.1.15.3 Recent developments
13.1.15.3.1 Service/Solution launches and approvals
13.1.15.3.2 Deals
13.1.16 PSI
13.1.16.1 Business overview
13.1.16.2 Services/Solutions offered
13.1.16.3 Recent developments
13.1.16.3.1 Service/Solution launches and approvals
13.1.16.3.2 Deals
13.1.16.3.3 Expansions
13.1.17 BIOAGILE THERAPEUTICS PRIVATE LIMITED
13.1.17.1 Business overview
13.1.17.2 Services/Solutions offered
13.1.18 FIRMA CLINICAL RESEARCH
13.1.18.1 Business overview
13.1.18.2 Services/Solutions offered
13.1.19 ACCULAB LIFE SCIENCES
13.1.19.1 Business overview
13.1.19.2 Services/Solutions offered
13.1.20 NOVOTECH
13.1.20.1 Business overview
13.1.20.2 Services/Solutions offered
13.1.20.3 Recent developments
13.1.20.3.1 Deals
13.1.21 LINICAL
13.1.21.1 Business overview
13.1.21.2 Services/Solutions offered
13.1.21.3 Recent developments
13.1.21.3.1 Deals
13.1.21.3.2 Expansions
13.1.22 ADVANCED CLINICAL
13.1.22.1 Business overview
13.1.22.2 Services/Solutions offered
13.1.22.3 Recent developments
13.1.22.3.1 Deals
13.1.22.3.2 Expansions
13.2 OTHER PLAYERS
13.2.1 ALLUCENT
13.2.2 EMVENIO
13.2.3 GUIRES INC.
13.2.4 WORLDWIDE CLINICAL TRIALS
13.2.5 CTI CLINICAL TRIAL & CONSULTING

14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
14.3 CUSTOMIZATION OPTIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS